Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.

You may also be interested in...



Deals Of The Week: GSK’s Stealth Move To The Coasts

The British pharma opens new innovation centers in San Diego and Cambridge, Mass., to connect with those academic, business and venture investment communities. Also, Roche and Biogen Idec make moves in neurodegenerative disease, Retrophin makes two deals for different forms of the same drug, and GSK makes the latest alliance in the cancer immunology arena.

In One Stroke, Retrophin Acquires And Licenses Assets For Autism And Schizophrenia, Doubles Down On Oxytocin

Retrophin, the former rare disease specialist, announced an agreement to acquire Kyalin Biosciences, whose lead candidate is a synthetic oxytocin formulation for autism. On the same day, it licensed another intranasal formulation of oxytocin from Novartis, market-ready for an obstetric indication.

Start-Up Quarterly Statistics, Q3 2013

Start-up fundraising for Q3 2013 totaled $559.4 million, down from last quarter’s big rally ($907.2 million) but still up from the sluggish first quarter ($398.7 million). More than half of that money went to biopharma companies, a group which also received investments through alliances with equity provisions.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS076116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel